[Progress in vaccination against AIDS].
Two vaccination trials against AIDS viruses are reported. The first trial was a prophylactic vaccination carried out in the pig-tailed macaque (Macacca nemestrina) against simian immunodeficiency virus (SIV) variant PBj14. The immunogen was a Semliki forest virus (SFV) recombinant expressing SFV - PBj14 envelope protein. Vaccination did not prevent infection but protected the animals against the disease (a fulminant form of AIDS that kills the animal within 12-15 days). The second trial was a therapeutic vaccination carried out with HIV-I-infected hemophilic patients. The immunogen was a toxoïd of alpha interferons. (A toxoïd of alpha interferons is an inactivated and immunogenic preparation of alpha interferons). Vaccination induced the production of neutralizing anti alpha interferon antibody. As a result, circulating alpha interferon concentrations were drastically lowered and the clinical status of patients significantly improved.
Burny
A
A
UER Biologie moléculaire et Physiologie animale de la faculté des Sciences agronomiques de Gembloux.
D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000818:Animals; D006801:Humans; D008254:Macaca nemestrina; D018449:SAIDS Vaccines; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*
D016915:AIDS Vaccines; D018449:SAIDS Vaccines